BAF-312(SiponiMod)
|
|
|
- CAS-Nr.
- 1230487-00-9
- Englisch Name:
- BAF-312(SiponiMod)
- Synonyma:
- SiponiMod;Siponimod (BAF-312);SIPONIMOD; SIPONIMOD [INN]; BAF-312; BAF 312;(E)-1-(4-(1-(4-cyclohexyl-3-(trifluoromethyl)benzyloxyimino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid;CS-1753;Sinimod;Siponimod D11;Siponimod [INN];BAF-312(SiponiMod);Formyl sitagliptin d4
- CBNumber:
- CB62725945
- Summenformel:
- C29H35F3N2O3
- Molgewicht:
- 516.59
- MOL-Datei:
- 1230487-00-9.mol
|
BAF-312(SiponiMod) Eigenschaften
- Schmelzpunkt:
- 154 - 157°C
- Siedepunkt:
- 602.0±65.0 °C(Predicted)
- Dichte
- 1.24±0.1 g/cm3(Predicted)
- storage temp.
- Hygroscopic, Refrigerator, under inert atmosphere
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 2.69±0.20(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- InChIKey
- KIHYPELVXPAIDH-HNSNBQBZSA-N
- SMILES
- N1(CC2=CC=C(/C(=N/OCC3=CC=C(C4CCCCC4)C(C(F)(F)F)=C3)/C)C=C2CC)CC(C(O)=O)C1
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P302+P352 |
BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
BAF-312(SiponiMod) Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
S1p signaling is important for immune, cardiovascular, and CNS function.Like its FDA
approved predecessor fingolimod, siponimod is an oral S1p signaling modulator.While fin-
golimod binds four out of five known S1p receptors, siponimod is selective for receptor sub-
types 1 and 5. This selectivity may allow for an improved adverse event profile.
Verwenden
Siponimod is a functional sphingosine -1 phosphate (SIP) antagonist used in the treatment of multiple sclerosis and other central nervous system-related diseases in human subjects. .
Nebenwirkungen
Siponimod,2 mg/day, was studied in a Phase I placebo-controlled trial in patients with secondary progressive Ms.206The primary endpoint was time to 3 months confirmed dis- ability progression. There were substantive side effects from the drug，mainly increased liver transaminase concentrations,bradycardia, and bradyarrhythmia at treatment initiation.With subsequent siponimod administration，there was an increased incidence of macular edema, hypertension,varicella zoster reactivation, and convulsions compared to placebo. By grad- ually escalating the initial dose of siponimod, cardiac first-dose effects were reduced.While the results of this trial are encouraging,long- term safety issues may be a greater concern5or since persons with secondary progressive MS as a group are older,with a higher incidence of comorbidities that could preclude use of siponimod.
BAF-312(SiponiMod) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
BAF-312(SiponiMod) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 178)Lieferanten
- BAF-312(SiponiMod)
- 3-Azetidinecarboxylic acid, 1-[[4-[(1E)-1-[[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]-
- 1-(4-[1-[(E)-4-Cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl]-2-ethyl-benzyl)-azetidine-3-carboxylic acid
- BAF312 (Siponimod) 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
- Siponimod [INN]
- CS-1753
- BAF-312(SiponiMod) USP/EP/BP
- Siponimod D11
- SiponiMod
- (E)-1-(4-(1-(4-cyclohexyl-3-(trifluoromethyl)benzyloxyimino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid
- Siponimod (BAF-312)
- SIPONIMOD; SIPONIMOD [INN]; BAF-312; BAF 312
- 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
- Formyl sitagliptin d4
- Sinimod
- 1230487-00-9
- C29H35F3N2O3
- API
- Inhibitors
